Contineum Therapeutics, Inc. Class A Common Stock
CTNM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $284 | $389 | $387 | $387 |
| - Cash | $22 | $16 | $6 | $5 |
| + Debt | $6 | $193 | $138 | $5 |
| Enterprise Value | $268 | $567 | $520 | $387 |
| Revenue | $0 | $50 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$0 | $50 | -$0 | $0 |
| % Margin | – | 100% | – | – |
| EBITDA | -$42 | $24 | -$24 | -$28 |
| % Margin | – | 47.1% | – | – |
| Net Income | -$42 | $23 | -$24 | -$29 |
| % Margin | – | 45.4% | – | – |
| EPS Diluted | -2.18 | 0.9 | -0.97 | -1.15 |
| % Growth | -342.2% | 192.8% | 15.7% | – |
| Operating Cash Flow | -$33 | $19 | -$20 | -$26 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$33 | $19 | -$20 | -$26 |